Suppr超能文献

蛋白激酶 D3 通过选择性增加肥大转录因子的表达,成为病理性心肌肥厚的关键激活剂。

Protein kinase D3 is a pivotal activator of pathological cardiac hypertrophy by selectively increasing the expression of hypertrophic transcription factors.

机构信息

Department of Pharmacology, Nankai University School of Medicine, Nankai, Tianjin 300071, China.

出版信息

J Biol Chem. 2011 Nov 25;286(47):40782-91. doi: 10.1074/jbc.M111.263046. Epub 2011 Oct 4.

Abstract

Fetal cardiac gene reactivation is a hallmark of pathological cardiac hypertrophy (PCH) driven by cardiac transcription factors (TFs) such as nuclear factor of activated T-cells (NFATs). Nuclear import of dephosphorylated NFATs catalyzed by calcineurin (CaN) is a well-established hypertrophic mechanism. Here we report that NFATc4 expression is also up-regulated by newly expressed protein kinase D3 (PKD3) to induce PCH. In both in vitro and in vivo cardiac hypertrophic models, the normally undetectable PKD3 was profoundly up-regulated by isoproterenol followed by overt expression of cardiac TFs including NFATc4, NK family of transcription factor 2.5 (Nkx2.5), GATA4 and myocyte enhancer factor 2 (MEF2). Using gene silencing approaches, we demonstrate PKD3 is required for increasing the expression of NFATc4, Nkx2.5, and GATA4 while PKD1 is required for the increase in MEF2D expression. Upstream induction of PKD3 is driven by nuclear entry of CaN-activated NFATc1 and c3 but not c4. Therefore, PKD3 is a pivotal mediator of the CaN-NFATc1/c3-PKD3-NFATc4 hypertrophic signaling cascade and a potential new drug target for the PCH.

摘要

胎儿心脏基因再激活是由核因子激活 T 细胞(NFATs)等心脏转录因子(TFs)驱动的病理性心肌肥厚(PCH)的标志。钙调神经磷酸酶(CaN)催化的去磷酸化 NFAT 核内易位是一种成熟的肥厚机制。在这里,我们报告 NFATc4 的表达也被新表达的蛋白激酶 D3(PKD3)上调,以诱导 PCH。在体外和体内心肌肥厚模型中,异丙肾上腺素强烈上调了通常无法检测到的 PKD3,随后包括 NFATc4、NK 家族转录因子 2.5(Nkx2.5)、GATA4 和肌细胞增强因子 2(MEF2)在内的心脏 TF 明显表达。通过基因沉默方法,我们证明 PKD3 是增加 NFATc4、Nkx2.5 和 GATA4 表达所必需的,而 PKD1 是增加 MEF2D 表达所必需的。PKD3 的上游诱导是由 CaN 激活的 NFATc1 和 c3 但不是 c4 的核内进入驱动的。因此,PKD3 是 CaN-NFATc1/c3-PKD3-NFATc4 肥厚信号级联的关键介质,也是 PCH 的潜在新药物靶点。

相似文献

7

引用本文的文献

1
Potential role for protein kinase D inhibitors in prostate cancer.蛋白激酶 D 抑制剂在前列腺癌中的潜在作用。
J Mol Med (Berl). 2023 Apr;101(4):341-349. doi: 10.1007/s00109-023-02298-4. Epub 2023 Feb 27.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验